Abstract
Predictive factors are responsible in determining the recurrence risk and death related to cancer and therefore to stablish the natural history of the disease regardless the treatment performed. Predictive factors are those that determine the outcome to a treatment.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Recommended Reading
Allison KH, Kandalaft PL, Sitlani CM, Dintzis SM, Gown AM. Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing? Breast Cancer Res Treat. 2012;131(2):413–24. Algorithm based on pathological anatomy that suggests which patients do not need to undergo OncotypeDx analysis in the decision-making process.
Cardoso F, van’t Veer LJ, Bogaerts J, et al. J 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375(8):717–29. Results of the randomized study employing Mammaprint test.
Duffy MJ, Harbeck N, Nap M, et al. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer. 2017;75:284–98. European guideline encompassing the use of molecular signatures on initial breast cancer.
Harris LN, Ismaila N, McShane LM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:1134–50. ASCO’s guideline on the recommendations of molecular signatures. This publication was updated in 2017 after the publication of the MINDACT study.
Krop I, Ismaila N, Andre F, Bast RC, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. J Clin Oncol. 2017. Atualização da diretriz da ASCO publicada em 2016, com foco nos resultados do estudo randomizado MINDACT, ampliando a recomendação do teste Mammaprint. ASCO’s updated guideline published in 2016, emphasizing the results of the randomized MINDACT study, extending the recommendation of the Mammaprint test.
Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 2015;373(21):2005–14. Prospective analysis of the low risk group RS (<11) from the TAILORx study employing the Oncotype DX test.
Wishart GC, Bajdik CD, Dicks E, et al. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer. 2012;107(5):800–7. This study demonstrates the value of the PREDICT tool versus Adjuvant! and demonstrates that the PREDICT, incorporating the status of HER2, is more accurate.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Cruz, M.R., Buzaid, A.C. (2019). Prognostic Predictors: Genetic Signatures, Adjuvant!, and PREDICT. In: Novita, G., Frasson, A., Millen, E., Zerwes, F., Cavalcante, F. (eds) Breast Diseases. Springer, Cham. https://doi.org/10.1007/978-3-030-13636-9_29
Download citation
DOI: https://doi.org/10.1007/978-3-030-13636-9_29
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-13635-2
Online ISBN: 978-3-030-13636-9
eBook Packages: MedicineMedicine (R0)